Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 2
Submit an article Journal homepage
1,843
Views
26
CrossRef citations to date
0
Altmetric
Bariatric Medicine

Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects

Harold BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA; Correspondence[email protected]
,
Xavier Pi-SunyerNew York Obesity Research Center, Columbia University, New York, NY, USA;
,
Joanna Uddén HemmingssonCapio St Goran’s Hospital/Karolinska Institutet, Stockholm, Sweden;
,
Birgitte ClaudiusNovo Nordisk A/S, Søborg, Denmark;
,
Christine B. JensenNovo Nordisk A/S, Søborg, Denmark;
&
Luc Van GaalDepartment of Endocrinology, Diabetology and Metabolism, Faculty of Medicine, Antwerp University Hospital, Edegem, Belgium
Pages 225-229 | Received 07 Jul 2016, Accepted 11 Oct 2016, Published online: 06 Nov 2016

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Patrick M. O’Neil & Domenica M. Rubino. (2022) Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgraduate Medicine 134:sup1, pages 28-36.
Read now
Chen-Hsiu Lin, Li Shao, Yu-Mei Zhang, Yu-Ju Tu, Yuzhen Zhang, Brian Tomlinson, Paul Chan & Zhongmin Liu. (2020) An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy 21:3, pages 275-285.
Read now
Javier Gargallo-Vaamonde, Carolina M. Perdomo, Magdalena de la Higuera, Gema Frühbeck & Javier Salvador. (2019) Is pharmacotherapy enough for urgent weight loss in severely obese patients?. Expert Opinion on Pharmacotherapy 20:4, pages 367-371.
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Liraglutide for weight management: benefits and risks. Current Medical Research and Opinion 33:3, pages 537-539.
Read now

Articles from other publishers (22)

Brian W. Locke, Ainhoa Gomez‐Lumbreras, Chia Jie Tan, Teerawat Nonthasawadsri, Sajesh K. Veettil, Chanthawat Patikorn & Nathorn Chaiyakunapruk. (2024) The association of weight loss from anti‐obesity medications or bariatric surgery and apnea‐hypopnea index in obstructive sleep apnea. Obesity Reviews 25:4.
Crossref
Karly E. Masse & Van B. Lu. (2023) Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease. Frontiers in Endocrinology 14.
Crossref
Ioannis Akoumianakis, Anastasios Zagaliotis, Maria Konstantaraki & Theodosios D. Filippatos. (2023) GLP‐1 analogs and regional adiposity: A systematic review and meta‐analysis. Obesity Reviews.
Crossref
Harold Edward Bays, Shagun Bindlish & Tiffany Lowe Clayton. (2023) Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. Obesity Pillars 5, pages 100056.
Crossref
Luigi Barrea, Ludovica Verde, Pasquale Santangeli, Stefania Lucà, Annamaria Docimo, Silvia Savastano, Annamaria Colao & Giovanna Muscogiuri. (2023) Very low-calorie ketogenic diet (VLCKD): an antihypertensive nutritional approach. Journal of Translational Medicine 21:1.
Crossref
Marcin Hachuła, Michał Kosowski, Kaja Zielańska, Marcin Basiak & Bogusław Okopień. (2023) The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health—A Narrative Review. International Journal of Environmental Research and Public Health 20:3, pages 2122.
Crossref
Peter Rossing, M. Luiza Caramori, Juliana C.N. Chan, Hiddo J.L. Heerspink, Clint Hurst, Kamlesh Khunti, Adrian Liew, Erin D. Michos, Sankar D. Navaneethan, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Sophia Zoungas, Jonathan C. Craig, David J. Tunnicliffe, Marcello A. Tonelli, Michael Cheung, Amy Earley & Ian H. de Boer. (2022) Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney International 102:5, pages 990-999.
Crossref
Peter Rossing, M. Luiza Caramori, Juliana C.N. Chan, Hiddo J.L. Heerspink, Clint Hurst, Kamlesh Khunti, Adrian Liew, Erin D. Michos, Sankar D. Navaneethan, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Sophia Zoungas & Ian H. de Boer. (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International 102:5, pages S1-S127.
Crossref
Kathleen M. Dungan. (2022) A New Bar for Pharmacologic Weight Loss: Type 2 Diabetes Prevention. Diabetes Care 45:10, pages 2204-2206.
Crossref
Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge & Justin Tondt. (2022) Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2, pages 100018.
Crossref
Harold E Bays, Anandita Agarwala, Charles German, Priyanka Satish, Adedapo Iluyomade, Ramzi Dudum, Aarti Thakkar, Mahmoud Al Rifai, Anurag Mehta, Aneesha Thobani, Yousif Al-Saiegh, Adam J Nelson, Samip Sheth & Peter P. Toth. (2022) Ten things to know about ten cardiovascular disease risk factors – 2022. American Journal of Preventive Cardiology 10, pages 100342.
Crossref
Jialin Shao, Chen Li, Litao Bai, Xiaolin Ni, Shaoqin Ge, Jinghui Zhang & Hanqing Zhao. (2022) Recent evidence in support of traditional chinese medicine to restore normal leptin function in simple obesity. Heliyon 8:5, pages e09482.
Crossref
Harold E. Bays, Pam R. Taub, Elizabeth Epstein, Erin D. Michos, Richard A. Ferraro, Alison L. Bailey, Heval M. Kelli, Keith C. Ferdinand, Melvin R. Echols, Howard Weintraub, John Bostrom, Heather M. Johnson, Kara K. Hoppe, Michael D. Shapiro, Charles A. German, Salim S. Virani, Aliza Hussain, Christie M. Ballantyne, Ali M. Agha & Peter P. Toth. (2021) Ten things to know about ten cardiovascular disease risk factors. American Journal of Preventive Cardiology 5, pages 100149.
Crossref
国庆 邢. (2021) Research Progress of Liraglutide in Improving Obesity. Advances in Clinical Medicine 11:11, pages 5501-5506.
Crossref
Margery A. Connelly, Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui & Arun J. Sanyal. (2020) Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 52:4, pages 619-636.
Crossref
Xu Zhao, Kun Huang, Meijie Zheng & Junting Duan. (2019) Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocrine Disorders 19:1.
Crossref
Rosario Pastor & Josep A. Tur. (2019) Liraglutide for the Treatment of Obesity: Analyzing Published Reviews. Current Pharmaceutical Design 25:15, pages 1783-1790.
Crossref
H. Bays, C. Perdomo, E. Nikonova, R. Knoth & M. Malhotra. (2018) Lorcaserin and metabolic disease: weight‐loss dependent and independent effects. Obesity Science & Practice 4:6, pages 499-505.
Crossref
J. Rick Turner. (2018) Cardiodiabesity and Related Updates. Therapeutic Innovation & Regulatory Science 52:1, pages 4-6.
Crossref
Carolyn T. Bramante, Clare J. Lee & Kimberly A. Gudzune. (2017) Treatment of Obesity in Patients With Diabetes. Diabetes Spectrum 30:4, pages 237-243.
Crossref
R. L. Kolotkin & J. R. Andersen. (2017) A systematic review of reviews: exploring the relationship between obesity, weight loss and health‐related quality of life. Clinical Obesity 7:5, pages 273-289.
Crossref
Andre R. C. Barreto-Vianna, Marcia B. Aguila & Carlos A. Mandarim-de-Lacerda. (2017) Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation. Metabolic Brain Disease 32:5, pages 1735-1745.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.